Document is current
Any future updates will be listed below
-
Authors
Klöbl, Manfred
Prillinger, Karin
Diehm, Robert
Doganay, Kamer
Lanzenberger, Rupert
Poustka, Luise
Plener, Paul
Konicar, Lilian
-
Funding
Funding for this research was provided by:
Austrian Science Fund (KLI600B27, KLI600B27)
- License Information
-
More Information
Article History
Received: 29 September 2022
Accepted: 18 December 2022
First Online: 12 January 2023
Declarations
:
: The overall clinical trial and all parts presented here were conducted in accordance with the Declaration of Helsinki and the good scientific practice guidelines of the Medical University of Vienna. The project was approved by the institutional review board (EK-Nr.: 1850/2015). Informed assent was given by the participants and informed consent was provided by the parents/legal guardian.
: Not applicable.
: Rupert Lanzenberger received travel grants and/or conference speaker honoraria within the last three years from Bruker BioSpin MR and Heel, and has served as a consultant for Ono Pharmaceutical. He received investigator-initiated research funding from Siemens Healthcare regarding clinical research using PET/MR. He is a shareholder of the start-up company BM Health GmbH since 2019.
